Marie Fredslund Breinholt

Medicine & Life Sciences

1. Agammaglobulinaemia Tyrosine Kinase 29%
2. Automobiles 21%
3. Azacitidine 17%
4. B-Cell Lymphoma 100%
5. B-Lymphocytes 16%
6. Biomarkers 7%
7. Biopsy 12%
8. Blood Cells 9%
9. Bone Marrow Examination 6%
10. Calreticulin 27%
11. Cancer Vaccines 24%
12. carfilzomib 31%
13. Cellular Immunity 19%
14. Clinical Trials, Phase I 26%
15. daratumumab 67%
16. Delayed Hypersensitivity 11%
17. Epigenomics 17%
18. Epitopes 21%
19. Exome 5%
20. Exons 20%
21. Fluorescence In Situ Hybridization 10%
22. Follicular Lymphoma 34%
23. Genes 7%
24. Genetic Heterogeneity 23%
25. High-Throughput Nucleotide Sequencing 67%
26. Injection Site Reaction 11%
27. Lymphocytes 6%
28. Lymphoma 11%
29. Lymphoma, Large B-Cell, Diffuse 24%
30. Macrophages 13%
31. montanide ISA 51 9%
32. Multiple Myeloma 58%
33. Mutation 38%
34. Myelodysplastic Syndromes 29%
35. Neoplasm Antigens 21%
36. Neoplasms 18%
37. Non-Hodgkin's Lymphoma 40%
38. Peptides 38%
39. Progression-Free Survival 7%
40. Proteins 7%
41. Proto-Oncogene Proteins c-bcl-2 9%
42. Safety 6%
43. Staining and Labeling 7%
44. Subunit Vaccines 10%
45. Survival 6%
46. T-Lymphocytes 6%
47. Therapeutics 20%
48. Vaccination 34%
49. Vaccine Immunogenicity 6%
50. Vaccines 47%